Info

About Velocimed's Products: A patent foramen ovale (PFO) is a structural defect of the heart where a small hole at birth between the right and left atria (upper chambers of the heart) fails to close in infancy. An estimated 25% of the adult population has a PFO. Though usually considered benign, this condition has been associated with an elevated risk of a stroke. Over 200,000 patients worldwide who survive a stroke each year have a PFO and are potential candidates for PFO therapy. The Premere(TM) PFO closure system already is approved in Europe. Efforts to initiate a U.S. clinical study of the Premere(TM) system under an investigational device exemption (IDE) are underway. Embolic protection devices are used to help minimize the risk of heart attack or stroke if plaque or other debris are dislodged into the blood stream during interventional cardiology procedures. Interest in the embolic protection market has increased based on recent studies involving saphenous vein grafts (SVG) where a reduction of major adverse coronary events (MACE) occurred when other embolic protection devices were deployed. The Proxis(TM) device has CE Mark approval for SVG use in Europe and is currently being evaluated in the United States in a clinical study under an approved IDE granted by the FDA.